Integrating the Guardian Spatial Emanator Within AVENIR II
NCT: NCT07712263 · NOT_YET_RECRUITING
Brief Summary
This study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger. The objective is to assess whether Guardian can be feasibly, acceptably, and effectively delivered through the same community-based platform already used for door-to-door azithromycin distribution to children 1 to 59 months of age. Selected health center catchment areas in high-malaria-transmission settings in Niger will be randomized to integrated delivery or non-integrated delivery. The study will measure implementation outcomes including reach, coverage, acceptability, fidelity to protocol, costs, and product placement over time, and will also assess malaria-related clinic visits among children under 5 years of age using routine health facility data
Frequently Asked Questions
What is Integrating the Guardian Spatial Emanator Within AVENIR II?
Integrating the Guardian Spatial Emanator Within AVENIR II is a clinical trial registered under NCT07712263. Current status: NOT_YET_RECRUITING.
What is the status of NCT07712263?
The current status of NCT07712263 (Integrating the Guardian Spatial Emanator Within AVENIR II) is: NOT_YET_RECRUITING.
When did Integrating the Guardian Spatial Emanator Within AVENIR II start?
Integrating the Guardian Spatial Emanator Within AVENIR II started on 2026-12-01.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.